Faculté de Médecine, Université Paris-Saclay, 94270 Le Kremlin-Bicêtre, France.
INSERM UMR_S 999, Hypertension Pulmonaire, Physiopathologie et Innovation Thérapeutique, Hôpital Marie Lannelongue, 92350 Le Plessis-Robinson, France.
Biomolecules. 2020 Sep 1;10(9):1261. doi: 10.3390/biom10091261.
Pulmonary arterial hypertension (PAH) is a rare and severe cardiopulmonary disease without curative treatments. PAH is a multifactorial disease that involves genetic predisposition, epigenetic factors, and environmental factors (drugs, toxins, viruses, hypoxia, and inflammation), which contribute to the initiation or development of irreversible remodeling of the pulmonary vessels. The recent identification of loss-of-function mutations in (KCNK3 or TASK-1) and (SUR1), or gain-of-function mutations in (SUR2), as well as polymorphisms in (Kv1.5), which encode two potassium (K) channels and two K channel regulatory subunits, has revived the interest of ion channels in PAH. This review focuses on KCNK3, SUR1, SUR2, and Kv1.5 channels in pulmonary vasculature and discusses their pathophysiological contribution to and therapeutic potential in PAH.
肺动脉高压(PAH)是一种罕见且严重的心肺疾病,目前尚无治愈方法。PAH 是一种多因素疾病,涉及遗传易感性、表观遗传因素和环境因素(药物、毒素、病毒、缺氧和炎症),这些因素导致肺血管的不可逆重构的起始或发展。最近发现 (KCNK3 或 TASK-1)和 (SUR1)中的功能丧失性突变,或 (SUR2)中的获得性功能突变,以及编码两种钾(K)通道和两种 K 通道调节亚基的 (Kv1.5)中的多态性,使离子通道在 PAH 中的作用重新受到关注。本文重点介绍肺血管中的 KCNK3、SUR1、SUR2 和 Kv1.5 通道,并讨论它们在 PAH 中的病理生理作用及其治疗潜力。